Erratum: Erratum
- PMID: 36531909
- PMCID: PMC9755543
- DOI: 10.1177/11795484221127555
Erratum: Erratum
Abstract
[This corrects the article DOI: 10.1177/11795484221119316.].
© The Author(s) 2022.
Erratum for
-
Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19.Clin Med Insights Circ Respir Pulm Med. 2022 Aug 10;16:11795484221119316. doi: 10.1177/11795484221119316. eCollection 2022. Clin Med Insights Circ Respir Pulm Med. 2022. PMID: 35991210 Free PMC article.
References
-
- Jones RS, Smith PS, Berg PH, et al. Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine. January 2022. doi: 10.1177/11795484221119316 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
